Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers · Source last updated 2020-03-16
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Baseline (pre-dose Week1 Day1) and Weeks 5, 9, 17, 25, 33, 41, 49 and discharge/progression (disc/prog)
What was measured
Urine samples were collected for the analysis of following urine parameters: potential of hydrogen (pH), glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented.
Analysis population: All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
Groups in this outcome
Part 1: GSK525762 2 mg QD
Participants were administered once daily (QD) oral dose of 2 milligrams (mg) GSK525762.
Part 1: GSK525762 4 mg QD
Participants were administered once daily oral dose of 4 mg GSK525762.
Part 1: GSK525762 8 mg QD
Participants were administered once daily oral dose of 8 mg GSK525762.
Part 1: GSK525762 16 mg QD
Participants were administered once daily oral dose of 16 mg GSK525762.
Part 1: GSK525762 30 mg QD
Participants were administered once daily oral dose of 30 mg GSK525762.
Part 1: GSK525762 60 mg QD
Participants were administered once daily oral dose of 60 mg GSK525762.
Part 1: GSK525762 80 mg QD
Participants were administered once daily oral dose of 80 mg GSK525762.
Part 1: GSK525762 100 mg QD
Participants were administered once daily oral dose of 100 mg GSK525762.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
3
Part 1: GSK525762 4 mg QD
4
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
4
Part 1: GSK525762 60 mg QD
9
Part 1: GSK525762 80 mg QD
32
Part 1: GSK525762 100 mg QD
9
Reported measurements
Cellular casts; Week 9; n=0,0, 0, 0, 0,1,4,1
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
0
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
1
Part 1: GSK525762 80 mg QD
4
Part 1: GSK525762 100 mg QD
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Cellular casts; Week 17; n=0,0, 0, 0, 0,0,1,0
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
0
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
0
Part 1: GSK525762 80 mg QD
1
Part 1: GSK525762 100 mg QD
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Cellular casts; Disc/Prog; n=0,0,0,0,0,1,5,1
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
0
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
1
Part 1: GSK525762 80 mg QD
5
Part 1: GSK525762 100 mg QD
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
1
Part 1: GSK525762 60 mg QD
2
Part 1: GSK525762 80 mg QD
5
Part 1: GSK525762 100 mg QD
3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Hyaline casts;Week 9; n=0,1,0, 0,0,1,5,3
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
1
Part 1: GSK525762 80 mg QD
5
Part 1: GSK525762 100 mg QD
3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Glucose;Week 5; n=1,2,1,3,2,7,20,7
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
2
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
2
Part 1: GSK525762 60 mg QD
7
Part 1: GSK525762 80 mg QD
20
Part 1: GSK525762 100 mg QD
7
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
4
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
2
Not reported
Not reported
Not reported
Not reported
Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
1
Part 1: GSK525762 30 mg QD
1
Part 1: GSK525762 60 mg QD
3
Part 1: GSK525762 80 mg QD
12
Part 1: GSK525762 100 mg QD
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Glucose;Week 25; n=0,1,0,0,0,0,3,1
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
0
Part 1: GSK525762 80 mg QD
3
Part 1: GSK525762 100 mg QD
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
1
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
3
Part 1: GSK525762 80 mg QD
17
Part 1: GSK525762 100 mg QD
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Ketones;Week 5; n=1,2,1,3,2,7,20,7
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
2
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
2
Part 1: GSK525762 60 mg QD
7
Part 1: GSK525762 80 mg QD
20
Part 1: GSK525762 100 mg QD
7
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Ketones;Week 9; n=1,1,0,1,1,3,12,5
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
1
Part 1: GSK525762 30 mg QD
1
Part 1: GSK525762 60 mg QD
3
Part 1: GSK525762 80 mg QD
12
Part 1: GSK525762 100 mg QD
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Occult blood;Week 5; n=1,2,1,3,2,7,17,7
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
2
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
2
Part 1: GSK525762 60 mg QD
7
Part 1: GSK525762 80 mg QD
17
Part 1: GSK525762 100 mg QD
7
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Occult blood;Week 9; n=1,1,0,1,1,3,11,5
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
1
Part 1: GSK525762 30 mg QD
1
Part 1: GSK525762 60 mg QD
3
Part 1: GSK525762 80 mg QD
11
Part 1: GSK525762 100 mg QD
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
3
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Occult blood;Week 17; n=0, 1,0,0,0,0,5,3
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
0
Part 1: GSK525762 80 mg QD
5
Part 1: GSK525762 100 mg QD
3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Occult blood;Week 25; n=0,1,0,0,0,0,3,1
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
0
Part 1: GSK525762 80 mg QD
3
Part 1: GSK525762 100 mg QD
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Occult blood;Week 33; n=0,1,0,0,0,0,2,0
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
0
Part 1: GSK525762 80 mg QD
2
Part 1: GSK525762 100 mg QD
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Occult blood;Disc/Prog; n=0,1,0,1,0,3,17,2
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
1
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
3
Part 1: GSK525762 80 mg QD
17
Part 1: GSK525762 100 mg QD
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
pH;Week 5; n=1, 2, 1, 3,2,7,20,7
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
2
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
2
Part 1: GSK525762 60 mg QD
7
Part 1: GSK525762 80 mg QD
20
Part 1: GSK525762 100 mg QD
7
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
5
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
6
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
3
Not reported
Not reported
Not reported
Not reported
pH;Week 9; n=1,1,0,1,1,3,12,5
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
1
Part 1: GSK525762 30 mg QD
1
Part 1: GSK525762 60 mg QD
3
Part 1: GSK525762 80 mg QD
12
Part 1: GSK525762 100 mg QD
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
8
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
2
Not reported
Not reported
Not reported
Not reported
pH;Week 25; n=0,1,0,0,0,0,3,1
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
0
Part 1: GSK525762 80 mg QD
3
Part 1: GSK525762 100 mg QD
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
pH;Week 33; n=0,1,0,0,0,0,2,0
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
0
Part 1: GSK525762 80 mg QD
2
Part 1: GSK525762 100 mg QD
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
0
Not reported
Not reported
Not reported
Not reported
pH;Disc/Prog; n=0,1,0,1,0,3,17,2
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
1
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
3
Part 1: GSK525762 80 mg QD
17
Part 1: GSK525762 100 mg QD
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
9
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Protein;Week 5; n=1, 2,1,3,2,7,20,7
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
2
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
2
Part 1: GSK525762 60 mg QD
7
Part 1: GSK525762 80 mg QD
20
Part 1: GSK525762 100 mg QD
7
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
3
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
9
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
4
Not reported
Not reported
Not reported
Not reported
Protein;Week 9; n=1,1,0,1,1,3,12,5
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
1
Part 1: GSK525762 30 mg QD
1
Part 1: GSK525762 60 mg QD
3
Part 1: GSK525762 80 mg QD
12
Part 1: GSK525762 100 mg QD
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
7
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
3
Not reported
Not reported
Not reported
Not reported
Protein;Week 17; n=0,1,0,0,0,0,5,3
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
0
Part 1: GSK525762 80 mg QD
5
Part 1: GSK525762 100 mg QD
3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Protein;Week 25; n=0,1,0,0,0,0,3,1
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
0
Part 1: GSK525762 80 mg QD
3
Part 1: GSK525762 100 mg QD
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Protein;Disc/Prog; n=0,1,0,1,0,3,17,2
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
1
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
3
Part 1: GSK525762 80 mg QD
17
Part 1: GSK525762 100 mg QD
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
5
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Specific gravity;Week 5; n=1,2,1,3,2,7,20,7
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
2
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
3
Part 1: GSK525762 30 mg QD
2
Part 1: GSK525762 60 mg QD
7
Part 1: GSK525762 80 mg QD
20
Part 1: GSK525762 100 mg QD
7
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
5
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
7
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
5
Not reported
Not reported
Not reported
Not reported
Specific gravity;Week 9; n=1,1,0,1,1,3,12,5
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
1
Part 1: GSK525762 30 mg QD
1
Part 1: GSK525762 60 mg QD
3
Part 1: GSK525762 80 mg QD
12
Part 1: GSK525762 100 mg QD
5
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
6
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
4
Not reported
Not reported
Not reported
Not reported
Specific gravity;Week 17; n=0,1,0,0,0,0,5,3
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
0
Part 1: GSK525762 80 mg QD
5
Part 1: GSK525762 100 mg QD
3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
4
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
2
Not reported
Not reported
Not reported
Not reported
Specific gravity;Week 25; n=0,1,0,0,0,0,3,1
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
0
Part 1: GSK525762 80 mg QD
3
Part 1: GSK525762 100 mg QD
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Specific gravity;Week 33; n=0,1,0,0,0,0,2,0
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
0
Part 1: GSK525762 80 mg QD
2
Part 1: GSK525762 100 mg QD
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Specific gravity;Disc/Prog; n=0,1,0,1,0,3,16,2
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
1
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
3
Part 1: GSK525762 80 mg QD
16
Part 1: GSK525762 100 mg QD
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
6
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Specific gravity;Week 41; n=0,0,0,0,0,0,1,0
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
0
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
0
Part 1: GSK525762 80 mg QD
1
Part 1: GSK525762 100 mg QD
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Specific gravity;Week 49; n=0,0,0,0,0,0,1,0
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
0
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
0
Part 1: GSK525762 80 mg QD
1
Part 1: GSK525762 100 mg QD
0
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Leukocytes;Week 5; n=1,2,1,2,2,6,11,6
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
2
Part 1: GSK525762 8 mg QD
1
Part 1: GSK525762 16 mg QD
2
Part 1: GSK525762 30 mg QD
2
Part 1: GSK525762 60 mg QD
6
Part 1: GSK525762 80 mg QD
11
Part 1: GSK525762 100 mg QD
6
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 8 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
2
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
4
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
2
Not reported
Not reported
Not reported
Not reported
Leukocytes;Week 9; n=1,1,0,1,1,1,6,4
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
1
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
1
Part 1: GSK525762 30 mg QD
1
Part 1: GSK525762 60 mg QD
1
Part 1: GSK525762 80 mg QD
6
Part 1: GSK525762 100 mg QD
4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 2 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 30 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
3
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Leukocytes;Week 17; n=0,1,0,0,0,0,1,2
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
0
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
0
Part 1: GSK525762 80 mg QD
1
Part 1: GSK525762 100 mg QD
2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
1
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
0
Not reported
Not reported
Not reported
Not reported
Leukocytes;Disc/Prog; n=0,1,0,1,0,2,6,1
Analysis denominator · Participants
Group
Source count
Part 1: GSK525762 2 mg QD
0
Part 1: GSK525762 4 mg QD
1
Part 1: GSK525762 8 mg QD
0
Part 1: GSK525762 16 mg QD
1
Part 1: GSK525762 30 mg QD
0
Part 1: GSK525762 60 mg QD
2
Part 1: GSK525762 80 mg QD
6
Part 1: GSK525762 100 mg QD
1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Part 1: GSK525762 4 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 16 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 60 mg QD
0
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 80 mg QD
4
Not reported
Not reported
Not reported
Not reported
Part 1: GSK525762 100 mg QD
1
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG005
value
0
group Id
OG006
value
1
group Id
OG007
value
1
denoms
counts
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
1
group Id
OG006
value
4
group Id
OG007
value
1
units
Participants
title
Cellular casts; Week 9; n=0,0, 0, 0, 0,1,4,1
categories
measurements
group Id
OG006
value
1
denoms
counts
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
1
group Id
OG007
value
0
units
Participants
title
Cellular casts; Week 17; n=0,0, 0, 0, 0,0,1,0
categories
measurements
group Id
OG005
value
0
group Id
OG006
value
1
group Id
OG007
value
0
denoms
counts
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
1
group Id
OG006
value
5
group Id
OG007
value
1
units
Participants
title
Cellular casts; Disc/Prog; n=0,0,0,0,0,1,5,1
categories
measurements
group Id
OG001
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
2
group Id
OG007
value
1
denoms
counts
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
1
group Id
OG005
value
2
group Id
OG006
value
5
group Id
OG007
value
3
units
Participants
title
Hyaline casts;Week 5; n=0,1,0,0,1,2,5,3
categories
measurements
group Id
OG001
value
0
group Id
OG005
value
0
group Id
OG006
value
0
group Id
OG007
value
1
denoms
counts
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
1
group Id
OG006
value
5
group Id
OG007
value
3
units
Participants
title
Hyaline casts;Week 9; n=0,1,0, 0,0,1,5,3
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
4
group Id
OG007
value
2
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
2
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
2
group Id
OG005
value
7
group Id
OG006
value
20
group Id
OG007
value
7
units
Participants
title
Glucose;Week 5; n=1,2,1,3,2,7,20,7
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
1
group Id
OG007
value
1
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
1
group Id
OG005
value
3
group Id
OG006
value
12
group Id
OG007
value
5
units
Participants
title
Glucose;Week 9; n=1, 1, 0, 1,1,3,12,5
categories
measurements
group Id
OG001
value
0
group Id
OG006
value
0
group Id
OG007
value
1
denoms
counts
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
3
group Id
OG007
value
1
units
Participants
title
Glucose;Week 25; n=0,1,0,0,0,0,3,1
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG005
value
0
group Id
OG006
value
1
group Id
OG007
value
0
denoms
counts
group Id
OG000
value
0
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
0
group Id
OG005
value
3
group Id
OG006
value
17
group Id
OG007
value
2
units
Participants
title
Glucose;Disc/Prog; n=0, 1, 0,1,0,3,17,2
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
2
group Id
OG007
value
1
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
2
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
2
group Id
OG005
value
7
group Id
OG006
value
20
group Id
OG007
value
7
units
Participants
title
Ketones;Week 5; n=1,2,1,3,2,7,20,7
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG003
value
0
group Id
OG004
value
0
group Id
OG005
value
0
group Id
OG006
value
2
group Id
OG007
value
0
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
1
group Id
OG005
value
3
group Id
OG006
value
12
group Id
OG007
value
5
units
Participants
title
Ketones;Week 9; n=1,1,0,1,1,3,12,5
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
1
group Id
OG004
value
2
group Id
OG005
value
0
group Id
OG006
value
2
group Id
OG007
value
0
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
2
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
2
group Id
OG005
value
7
group Id
OG006
value
17
group Id
OG007
value
7
units
Participants
title
Occult blood;Week 5; n=1,2,1,3,2,7,17,7
denoms
counts
group Id
OG000
value
3
group Id
OG001
value
4
group Id
OG002
value
1
group Id
OG003
value
3
group Id
OG004
value
4
group Id
OG005
value
9
group Id
OG006
value
32
group Id
OG007
value
9
units
Participants
description
Urine samples were collected for the analysis of following urine parameters: potential of hydrogen (pH), glucose, protein, occult blood, ketones, specific gravity, erythrocytes and leukocytes. Baseline is the most recent, non-missing value prior to or on the first study treatment dose date. Only parameters and time points with non-zero values for any increase have been presented.
groups
description
Participants were administered once daily (QD) oral dose of 2 milligrams (mg) GSK525762.
id
OG000
title
Part 1: GSK525762 2 mg QD
description
Participants were administered once daily oral dose of 4 mg GSK525762.
id
OG001
title
Part 1: GSK525762 4 mg QD
description
Participants were administered once daily oral dose of 8 mg GSK525762.
id
OG002
title
Part 1: GSK525762 8 mg QD
description
Participants were administered once daily oral dose of 16 mg GSK525762.
id
OG003
title
Part 1: GSK525762 16 mg QD
description
Participants were administered once daily oral dose of 30 mg GSK525762.
id
OG004
title
Part 1: GSK525762 30 mg QD
description
Participants were administered once daily oral dose of 60 mg GSK525762.
id
OG005
title
Part 1: GSK525762 60 mg QD
description
Participants were administered once daily oral dose of 80 mg GSK525762.
id
OG006
title
Part 1: GSK525762 80 mg QD
description
Participants were administered once daily oral dose of 100 mg GSK525762.
id
OG007
title
Part 1: GSK525762 100 mg QD
param Type
COUNT_OF_PARTICIPANTS
population Description
All Treated Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles).
reporting Status
POSTED
time Frame
Baseline (pre-dose Week1 Day1) and Weeks 5, 9, 17, 25, 33, 41, 49 and discharge/progression (disc/prog)
title
Number of Participants With Maximum Urinalysis Change From Baseline-Part 1 QD
Triangle